Clinical Research Directory
Browse clinical research sites, groups, and studies.
Amobarbital and Cardiopulmonary Bypass
Sponsor: Tongji Hospital
Summary
Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.
Official title: The Effect of Amobarbital on Myocardial Protection and Prognosis in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-02-01
Completion Date
2026-03-01
Last Updated
2025-03-21
Healthy Volunteers
No
Conditions
Interventions
Amobarbital
Amobarbital 1mg/kg is given prior to cardiopulmonary bypass
Midazolam
midazolam 0.1mg/kg is given prior to cardiopulmonary bypass
Locations (1)
Tongji hospital
Wuhan, Hubei, China